Condition Spotlight

BPC-157 for Interstitial Cystitis: The Pilot Study Every Woman Should Know About

June 20, 2026 12 min read FemPeptides Research Team

Affiliate Disclosure: FemPeptides.com participates in affiliate programs. Some links on this page are affiliate links, meaning we may earn a commission at no extra cost to you if you make a purchase. This supports our ability to provide free, research-backed content. All recommendations are based on independent evaluation.

Interstitial cystitis (IC) — also called bladder pain syndrome — is one of the most frustrating conditions in women’s health. Chronic bladder pain, urinary urgency, frequency, and pelvic discomfort with no clear infectious cause and limited treatment options. It affects women at roughly 5x the rate of men, and many women cycle through years of misdiagnosis before receiving proper care.

BPC-157 has generated significant interest in the IC community, and one pilot study provides the first direct human evidence.

The Pilot Study: 12 Women, Remarkable Results

A pilot study of BPC-157 in women with interstitial cystitis showed 80-100% symptom resolution in 10 of 12 participants. The study used oral BPC-157 administration. While the sample size is small and the study was not a randomized controlled trial, the magnitude of response is notable in a condition where even modest improvement is considered a win.

This study is referenced in the BPC-157 PCAC submission and may factor into the committee’s evaluation on July 23, 2026.

Why BPC-157 Makes Mechanistic Sense for IC

BPC-157’s relevance to IC involves multiple overlapping mechanisms:

Mucosal protection: IC involves damage to the bladder’s protective glycosaminoglycan (GAG) layer. BPC-157 protects mucosal surfaces throughout the GI tract; the bladder’s transitional epithelium shares protective mechanisms with gut mucosa.
Anti-inflammatory: IC involves chronic inflammation of the bladder wall. BPC-157 reduces pro-inflammatory cytokines.
Nitric oxide modulation: The NO system is dysregulated in IC. BPC-157 interacts with the NO system to normalize vascular and inflammatory signaling.
Angiogenesis: BPC-157 promotes healthy blood vessel formation, which supports tissue repair in the chronically inflamed bladder wall.

Oral vs Injectable for IC

The pilot study used oral BPC-157, which is significant. BPC-157 is uniquely acid-stable, surviving the GI tract intact. For bladder conditions, oral administration may be advantageous because the peptide or its active metabolites may reach the bladder through systemic circulation and renal excretion. However, the exact pharmacokinetic pathway from oral ingestion to bladder tissue effect is not fully characterized.

Complementary Peptides for IC

KPV — Anti-Inflammatory Support

KPV reduces the same pro-inflammatory cytokines (TNF-alpha, IL-6) implicated in IC pathology. As a small tripeptide, it may complement BPC-157’s mucosal protection with targeted cytokine reduction.

Thymosin Alpha-1 — Immune Regulation

Some IC researchers believe the condition has an autoimmune component. Thymosin Alpha-1’s immune-modulating properties — approved in 35+ countries for immune support — may be relevant for women whose IC has autoimmune features.

BioPure Peptides

Code: POWER

BPC-157 (oral and injectable), KPV, Thymosin Alpha-1. Third-party tested.

Shop BPC-157 →Shop KPV →

Midwest Peptide

Code: POWER — 10% Off

BPC-157 with COAs on every page. Free shipping.

Shop BPC-157 →

Apollo Peptide Sciences

Verified COAs

BPC-157 with independent testing.

Shop BPC-157 →

Frequently Asked Questions

Can BPC-157 help with interstitial cystitis?

A pilot study showed 80-100% symptom resolution in 10 of 12 women with IC using oral BPC-157. While this is promising, the study was small and not a randomized controlled trial. Larger studies are needed. Discuss with your urologist or urogynecologist.

Should I take BPC-157 orally or injectable for IC?

The pilot study showing IC benefit used oral BPC-157. Oral administration may be advantageous for bladder conditions because the peptide reaches the bladder through systemic circulation. BPC-157 is uniquely acid-stable, making oral administration viable.

What is interstitial cystitis?

Interstitial cystitis (IC) or bladder pain syndrome is a chronic condition causing bladder pain, urinary urgency and frequency, and pelvic discomfort without an identifiable infectious cause. It affects women at approximately 5 times the rate of men.

Is BPC-157 being reviewed by the FDA for IC?

BPC-157 is scheduled for PCAC review on July 23, 2026, for potential inclusion on the 503A Bulk Drug Substances List. The IC pilot study is referenced in the submission materials. A positive recommendation would allow compounding pharmacies to prepare BPC-157 with a prescription.

Find Your Peptide Match

Take our 60-second quiz for personalized peptide recommendations based on your goals and life stage.

Take the Quiz →